Drugs / Ac-225 rosopatamab tetraxetan
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06549465 | Aug 2024 → Apr 2027 expected | castration-resistant prostate carcinoma | Convergent Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ac-225 rosopatamab tetraxetan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06549465 ↗ |
| Modality | Monoclonal antibody | “PSMA-directed radioantibody (rosopatamab tetraxetan, conjugated to either In-111 or Ac-225)” NCT06549465 ↗ |
| Route | Intravenous | “45 kBq/kg Ac-225 rosopatamab tetraxetan will be administered as an IV infusion over a period of 10 minutes.” NCT06549465 ↗ |